The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study

We aimed to evaluate the current nationwide trend, efficacy, safety, and quality of life (QoL) profiles of hormone treatment in real-world practice settings for prostate cancer (PCa) patients in Korea. A total of 292 men with any biopsy-proven PCa (TanyNanyMany) from 12 institutions in Korea were in...

Full description

Saved in:
Bibliographic Details
Published in:Asian journal of andrology 2019-03, Vol.21 (2), p.115-120
Main Authors: Kim, Jung Kwon, Kim, Jung Jun, Gang, Taek Won, Kwon, Tae Kyun, Kim, Hong Sup, Park, Seung Chul, Park, Jae-Shin, Park, Jong-Yeon, Yoon, Seok Joong, Jeon, Youn-Soo, Cho, Jin Seon, Joo, Kwan Joong, Hong, Sung-Hoo, Byun, Seok-Soo
Format: Article
Language:English
Subjects:
Aged
Androgen Antagonists - therapeutic use
Androgens
Antineoplastic Agents, Hormonal - therapeutic use
Cancer patients
Cancer research
Cancer therapies
Cancer treatment
Cholesterol - blood
Drug therapy
Drug Therapy, Combination
Glycoproteins
Gonadotropins
Hormones
Humans
Laboratories
Leuprolide - therapeutic use
Luteinizing hormone
Male
Metastasis
Middle Aged
Observational studies
Original
Patient compliance
Patients
Pituitary hormones
Prostate cancer
Prostatic Neoplasms - blood
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Quality of Life
Receptors, LHRH - agonists
Republic of Korea
Review boards
Smooth muscle
Studies
Testosterone
Testosterone - blood
Treatment Outcome
Triglycerides - blood
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to evaluate the current nationwide trend, efficacy, safety, and quality of life (QoL) profiles of hormone treatment in real-world practice settings for prostate cancer (PCa) patients in Korea. A total of 292 men with any biopsy-proven PCa (TanyNanyMany) from 12 institutions in Korea were included in this multi-institutional, observational study of prospectively collected data. All luteinizing hormone-releasing hormone (LHRH) agonists were allowed to be investigational drugs. Efficacy was defined as (1) the rate of castration (serum testosterone ≤50 ng dl ) at 4-week visit and (2) breakthrough (serum testosterone >50 ng dl after castration). Safety assessments included routine examinations for potential adverse events, laboratory tests, blood pressure, body weight, and bone mineral density (BMD, at baseline and at the last follow-up visit). QoL was assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26). The most common initial therapeutic regimen was LHRH agonist with anti-androgen (78.0%), and the most commonly used LHRH agonist for combination and monotherapy was leuprolide (64.0% for combination and 58.0% for monotherapy). The castration and breakthrough rates were 78.4% and 6.6%, respectively. The laboratory results related to dyslipidemia worsened after 4 weeks of hormone treatment. In addition, the mean BMD T-score was significantly lower at the last follow-up (mean: -1.950) compared to baseline (mean: -0.195). The mean total EPIC-26 score decreased from 84.8 (standard deviation [s.d.]: 12.2) to 78.3 (s.d.: 8.1), with significant deterioration only in the urinary domain (mean: 23.5 at baseline and 21.9 at the 4-week visit). These findings demonstrate the nationwide trend of current practice settings in hormone treatment for PCa in Korea.
ISSN:1008-682X
1745-7262
DOI:10.4103/aja.aja_95_18